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BACKGROUND Unfortunately, no any vaccine against leishmaniasis has been developed for human use. Therefore, a vaccine 
based on total Leishmania antigens could be a good and economic approach; and there are different methodologies to obtain 
these antigens. However, it is unknown whether the method to obtain the antigens affects the integrity and immune response 
caused by them.
OBJECTIVES to compare the protein profile and immune response generated by total L. amazonensis antigens (TLA) produced 
by different methods, as well as to analyse the immune response and protection by a first-generation vaccine formulated with 
sonicated TLA (sTLA) and polyinosinic:polycytidylic acid [Poly (I:C)].
METHODS TLA were obtained by four different methodologies and their integrity and immune response were evaluated. Finally, 
sTLA was formulated with Poly (I:C) and their protective immune response was measured.
FINDINGS sTLA presented a conserved protein profile and induced a strong immune response. In addition, Poly (I:C) improved the 
immune response generated by sTLA. Finally, sTLA + Poly (I:C) formulation provided partial protection against L. amazonensis 
infection.
MAIN CONCLUSIONS The protein profile and immune response depend on the methodology used to obtain the antigens. Also, 
the formulation sTLA + Poly (I:C) provides partial protection against cutaneous leishmaniasis in mice.
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Leishmaniasis is an anthropozoonotic disease caused 
by intracellular protozoa belonging to the Leishmania 
genus. It is transmitted between animals and humans by 
the bite of an infected Phlebotomine female. This dis-
ease is considered a growing public health problem as a 
consequence of the tropicalisation of continents.(1) It is 
also considered a neglected disease by the World Health 
Organization, due to the fact that it mainly affects low 
income populations with limited access to health care.
Different clinical manifestation can be caused by 
different species of Leishmania: cutaneous, mucocuta-
neous and visceral leishmaniasis. However, cutaneous 
leishmaniasis can be presented as localised, diffuse and 
atypical.(2) Particularly, L. amazonensis causes local-
ised cutaneous leishmaniasis. Nevertheless, this specie 
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has been isolated from patients with diffuse cutaneous 
and mucocutaneous leishmaniasis,(3) and some cases of 
visceral leishmaniasis by L. amazonensis have been de-
scribed in humans and dogs.(4)
Currently, there is not any approved vaccine against 
human leishmaniasis.(5) Nevertheless, several vaccine for-
mulations are under evaluation in preclinical(6,7,8) and clin-
ical trials (ClinicalTrials.gov Identifier: NCT02894008 
and NCT03969134). The need to induce a Th1-type im-
mune response in order to obtain protection was shown in 
Leishmania-murine models protection studies and in the 
immune profiles of self-healed individuals.(9)
First-generation Leishmania vaccines containing to-
tal Leishmania antigens are proposed as an economic 
strategy to prevent leishmaniasis,(10) which is an impor-
tant point in low income countries, where this disease is 
endemic. In this type of vaccine formulations, antigens 
have been produced by different methodologies based 
on the promastigote form: cycles of freezing and thaw-
ing, ultrasound, autoclaving, and pasteurisation.(11,12,13,14) 
Notably, only this kind of vaccines against human leish-
maniasis has been evaluated in phase III clinical trials.(15)
Few studies have been reported about the antigenic 
profile of total Leishmania antigens.(13,16) To date, no 
study has been conducted for the comparative assess-
ment of the immune response generated by total Leish-
mania antigens produced by different methodologies.
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The development of new vaccine strategies should 
be based on recent knowledge of the innate immune 
response, which can be activated by molecular patterns 
associated with pathogens through the activation of Toll-
like receptors (TLRs). This activation has an important 
role in the direction of the acquired immune response. 
TLRs agonists have shown promising therapeutic and 
prophylactic effects in disease models. It is important to 
remark that TLR-4 and TLR-9 agonists have been ap-
proved to be used as adjuvants in human vaccines.(17) We 
recently reported that a synthetic double-stranded RNA 
TLR-3 agonist [Poly (I:C)] formulated with freezing and 
thawing TLA triggers a protective immune response.(6) 
There is a lot of evidence that demonstrates the capacity 
of Poly (I:C) to induce an activation of antigen presenta-
tion cells (APC), a Th1-like immune response as well as 
generate memory T and B cells.(18)
In the present study, we evaluated the antigenic 
profile and the immune response generated by TLA 
obtained from promastigotes by cycles of freezing 
and thawing (fTLA), ultrasound (sTLA), autoclav-
ing (aTLA), and pasteurisation (pTLA). After that, we 
selected the methodology that generated a more con-
served antigenic profile and the antigens that generated 
greater immune response, to be formulated with a TLR-
3 agonist. Finally, we evaluated the capacity of this for-
mulation to mediate a Th1-like immune response and 
to provide protective immunity against L. amazonensis 
infection in BALB/c mice.
MATERIALS AND METHODS
Parasite cultures and methodologies used to obtain 
TLA - L. amazonensis promastigotes (MHOM/VE/84/
MEL) were grown in NNN (Novy-MacNeal-Nicolle) 
medium and their infectivity was maintained by serial 
passages in mice, as described previously.(19)
The TLA were obtained from L. amazonensis pro-
mastigotes, which were grown at their late logarithmic 
phase; afterwards, they were harvested by centrifugation 
and washed three times with phosphate-buffered saline 
(PBS). Four different methodologies were used to disrupt 
the promastigotes: one cycle of autoclaving at 121ºC for 15 
min (aTLA);(11) five cycles of freezing (-80ºC) and thaw-
ing (56ºC) (fTLA);(12) one cycle of pasteurisation at 56ºC 
for 30 min (pTLA);(13) and one cycle of ultrasound at 40 
W for 1 min at 4ºC (sTLA).(14) The protein content of each 
TLA was measured by bicinchoninic acid assay following 
manufacturing instructions (Thermo-Scientific).
Analysis of TLA protein profile - Sixty µg of each 
TLA and promastigote culture (fresh) were separated 
and analysed by electrophoresis in 12.5% sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) under reducing conditions and stained with Coo-
masie Blue R-250.
Densitometric analysis and molecular weight deter-
minations of each TLA protein profile were performed 
by Fiji ImageJ software version 2.0 [US National Insti-
tutes of Health (NIH); http://rsb.info.nih.gov/ij/].
Finally, the level of bacterial endotoxin was deter-
mined using the Gel Clot LAL Assay (Associates of 
Cape Cod, Inc. Falmouth, MA, USA), at the microbio-
logical unit of Microquim Inc, Contract Scientific Re-
search Laboratory (Buenos Aires, Argentina).
Animals - Inbred female BALB/c mice (six-to-eight-
week old) were used in this study. Mice were kept in stan-
dard conditions with barriers as well as controlled light 
cycle and temperature. Food and water were provided ad 
libitum. Two independent experiments were carried out.
Ethics - All animals were cared for in accordance 
with the Guiding Principles in the Care and Use of Ani-
mals of the US NIH. All procedures performed in studies 
involving animals were under the ethical standards and 
were approved by the Institutional Animal Care and Use 
Committee of the School of Medical Science, Universi-
dad Nacional de Cuyo (protocol approval no. 80/2016).
Immunisation scheme - In order to compare the im-
mune response of animals to each TLA, four animals 
per group were injected twice every 21 days with 100 
µg of aTLA, fTLA, pTLA or sTLA without adjuvant by 
subcutaneous route into the interscapular zone; whereas 
the control group received PBS.
In order to evaluate the immune response and protec-
tion generated by a first-generation vaccine, 12 animals 
per group were injected three times every 14 days with: 
PBS (control); 100 µg of sTLA alone or with 50 µg of 
high molecular weight Poly (I:C) (Invivogen).
Humoral immune response - Anti-TLA total IgG, 
IgG1 and IgG2a subclasses were measured by enzyme-
linked immunosorbent assay (ELISA), as previously de-
scribed.(19) Data are represented as the mean ± standard 
error of mean (SEM) of optical density (OD) values of 
the vaccinated group.
Cellular immune response
In vitro culture cells - Two weeks after their last im-
munisation, animals were sacrificed and their spleens 
were removed and homogenised in supplemented RPMI-
1640 medium (Gibco) containing 10% foetal bovine 
serum (FBS), 100 IU/mL penicillin, 100 mg/mL strep-
tomycin and β-mercaptoethanol. Red blood cells were 
disrupted using ammonium-chloride-potassium lysing 
buffer. Splenocytes were incubated in triplicate at 5 x 
105 cells per well into 96-wells-flat-bottom culture plates 
at 37ºC in 5% CO2 and stimulated for 72 h with 1 µg 
of the same TLA to the one used for immunisation or 
supplemented  medium alone.(11)
Cytokines measurement - Levels of IFN-γ, IL-4 and 
IL-10 cytokines were determined in the supernatant of 
stimulated splenocytes by OptEIA ELISA Kits accord-
ing to manufacturing instructions (BD Pharmingen). 
Values are represented as means ± SEM of pg/mL of 
each cytokine.
In vitro cell proliferation - To determine cell prolif-
eration after 72 h of stimulation,(20) splenocytes were in-
cubated with 0.5 mg/mL of Thiazolyl Blue Tetrazolium 
Bromide (MTT, Sigma) for 4 h. After discarding the su-
pernatants, formazan crystals from cells were dissolved 
with 100 µL of dymethil sulphoxide (DMSO). The ab-
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sorbance was read at 570 nm and the proliferation index 
(PI) was calculated according to the following formula:
PI =
       (OD value from stimulated cell)      
              (OD value from non-stimulated cell)
Non-stimulated cells from each group were used 
as control for proliferation. Results are represented as 
means ± SEM of proliferation index (ratio of unstimu-
lated control).
Parasite challenge and infection progression - Six 
animals per group immunised with PBS, sTLA and 
sTLA + Poly (I:C) were infected on the right footpad 
(RFP) with 1 x 104 L. amazonensis promastigotes at 
their stationary phase.(21) The swelling of RFP was mea-
sured weekly using digital caliper (SCHWYZ, ED-10P) 
until 11 weeks after infection. The value for uninfected 
footpads was subtracted from each infected footpad to 
estimate the lesion size. Results were represented as mm 
of footpad swelling.
Splenic index - The splenic index was used as an 
indicator of parasite visceralisation. Eleven weeks af-
ter challenge, mice were weighted, sacrificed and their 
spleens removed and weighted to calculate splenic index 
according to the following formula:
Splenic index =
    (Spleen weight)
                                            (Body weight)     * 100
Determination of parasite burden by limit dilution 
- Parasite burden was determined by limit dilution 11 
weeks after challenge following a protocol described.
(22) Briefly, mice were sacrificed and their infected foot-
pads were removed and homogenised in 1 mL of supple-
mented RMPI 1640 medium. The suspension was plated 
in 96-wells plate and 10-fold dilutions were made and 
incubated at 26ºC for 14 days in order to assess viable 
parasites under optic microscopy. The wells containing 
motile promastigotes were identified and the number of 
viable parasites was determined from the highest dilu-
tion at which promastigotes had grown. The results were 
represented as –Log number of parasite.
Statistical analysis - In order to establish statisti-
cally significant differences, the data were analysed by 
analysis of variance (ANOVA), using Graphpad prism 
software version 5.00 (La Jolla California USA, www.
graphpad.com).
RESULTS
sTLA has a conserved protein profile - The SDS-
PAGE profiles from fresh promastigotes, aTLA, fTLA, 
pTLA, and sTLA are shown in Fig. 1A. The integrity of 
proteins in sTLA and fresh extracts have notable simi-
larity in the intensity and relative mobility of protein 
profile, widely distributed in a range of 25 to 250 kDa. 
Conversely, patterns of aTLA, fTLA, pTLA are clearly 
distinct with a smaller number of conserved bands. In 
addition, a densitometric analysis and molecular weight 
(MW) quantification of protein profile were performed, 
with results presented in kDa (Fig. 1B). A more intense 
band of 52 kDa was observed mainly in fresh and sTLA.
The endotoxin concentration of each TLA was less 
than 500 EU/mL. The recommendation of < 500 EU/mL 
for inactivated vaccines is based on the complex nature 
of these vaccines containing multiple antigens.(23)
sTLA induces a strong humoral immune response - 
Animals were injected twice at 3-week intervals with PBS 
(control), aTLA, fTLA, pTLA, and sTLA by subcutaneous 
route to determine if the methodology employed to obtain 
TLA could induce differential immune response. Specific 
anti-Leishmania IgG and its subclasses, IgG1 and IgG2a, 
were measured by ELISA two weeks after boost.
Mice that received sTLA showed higher IgG levels (p 
< 0.001), followed by mice injected with pTLA (p < 0.05), 
while aTLA and fTLA did not show statistically signifi-
cant increase in comparison to the control group (Fig. 2A).
Furthermore, mice injected with sTLA showed the 
highest IgG1 levels (p < 0.001) followed by mice that 
received pTLA (p < 0.05). In spite of the fact that IgG2a 
levels were not significant for all groups, sTLA showed a 
tendency to reach higher levels than other experimental 
groups (Fig. 2B, C).
sTLA increased IFN-γ levels and cell proliferation - 
We performed antigen-specific stimulatory spleen cells 
cultures from immunised mice to determine whether 
TLA-responder cells secrete Th polarised cytokines. 
Fig. 1: protein profile of total Leishmania amazonensis antigens 
(TLA). Sixty μg of total protein from fresh (lane 2), autoclaving 
TLA (aTLA) (lane 3), freezing and thawing TLA (fTLA) (lane 4), 
pasteurisation TLA (pTLA) (lane 5) and sonicated TLA (sTLA) 
(lane 6) were analysed by electrophoresis on a sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (12.5%). 
Molecular weight markers are shown in lane 1, with corresponding 
kDa on the left. The gel was stained with Coomassie blue (A). Den-
sitometric analysis and MW determination in kDa (B).
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As it can be seen in Fig. 3, both fTLA and sTLA in-
duced an intense IFN-γ production in contrast with the 
control group (p ˂ 0.05). When IL-4 production was de-
termined, fTLA and pTLA displayed higher levels than 
the control group (p ˂ 0.001 and p ˂ 0.05). Finally, only 
fTLA induced a marked increase in IL-10 production 
(p ˂ 0.01). These results suggest that fTLA displayed a 
striking reactivity but rising different Th profiles such 
as Th1, Th2 and Tr1. In contrast, sTLA induced an in-
crease of IFN-γ, with low IL-4 and IL-10 levels. In addi-
tion, fTLA, pTLA and sTLA induced cell proliferation; 
however, only sTLA displayed a statistically significant 
increase compared with the control group (Fig. 3D).
Altogether, these data highly suggest that sTLA dis-
played higher IFN-γ level and cellular proliferation, with 
lower IL-10 and lL-4 levels than the other TLA being 
eligible to perform a T cell-mediated vaccine.
sTLA formulated with Poly (I:C) enhances humoral 
immune responses - In order to improve the immune 
response toward a Th1 profile, sTLA was formulated 
with Poly (I:C) as adjuvant. Mice were immunised three 
times at 2-week intervals with PBS (control), sTLA and 
sTLA + Poly (I:C) and antibody levels were measured.
After the first boost, vaccine formulation contain-
ing sTLA and sTLA + Poly (I:C) induced an statistically 
significant increase of IgG antibodies in comparison to 
control group (p < 0.001). However, immunisation with 
sTLA + Poly (I:C) induced higher IgG levels than sTLA 
alone (p < 0.001) (Fig. 4A).
In addition, mice immunised with sTLA + Poly (I:C) 
showed significantly higher IgG1 levels than sTLA alone 
(p < 0.01) as well as the control group (p < 0.001) (Fig. 
4B). It was remarkable that mice immunised with sTLA 
+ Poly (I:C) showed significantly superior IgG2a levels 
as compared to sTLA alone and the control group (p < 
0.001) (Fig. 4C). In agreement with this, the IgG2a/IgG1 
ratio was higher in the sTLA + Poly (I:C) formulation 
(Fig. 4D). In conclusion, the combination of sTLA with 
Poly (I:C) induced a strong and Th1/Th2 balanced hu-
moral immune response.
Fig. 2: humoral immune response in mice injected with different total Leishmania amazonensis antigens (TLA). Anti-Leishmania IgG antibod-
ies (A) using serum samples dilution (1:500) obtained two weeks after boost. Anti-Leishmania IgG1 (B) and IgG2a (C) antibodies using serum 
samples dilution (1:1000) obtained two weeks after boost. Results are represented as mean ± standard error of mean (SEM) of optical density 
(OD) values obtained from four animals per groups. Asterisks indicate significant differences in comparison to the control group: *p ˂ 0.05; 
***p ˂ 0.001; ns: not significant by analysis of variance (ANOVA).
Fig. 3: cellular immune response generated in mice injected with different total Leishmania amazonensis antigens (TLA). Cytokines levels of 
IFN-γ (A), IL-4 (B), IL-10 (C) measured by enzyme-linked immunosorbent assay (ELISA) using supernatant of splenocytes stimulated with TLA 
two weeks after boost; results are represented as mean ± standard error of mean (SEM) of cytokine concentration (pg). Cell proliferation assay 
(D) determined by MTT on stimulated splenocytes two weeks after boost; results are represented as mean ± SEM of proliferation index (ratio of 
unstimulated control). Asterisks indicate significant differences in comparison to the control group: *p ˂ 0.05; **p ˂ 0.01; ***p ˂ 0.001.
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sTLA formulated with Poly (I:C) induces a strong 
Th1-like cellular immune response - Two weeks after the 
last boost, cytokines production and cell proliferation 
were analysed on splenocyte culture. As can be seen in 
Fig. 5, sTLA + Poly (I:C) generated higher IFN-γ pro-
duction than sTLA as compared to the control group (p 
< 0.001 and p < 0.05). Additionally, Poly (I:C) also in-
creased sTLÁs ability to secrete IL-4 (p < 0.05). Fur-
thermore, sTLA + Poly (I:C) produced significantly low-
er IL-10 levels than sTLA group (p < 0.001). Although 
both sTLA and sTLA + Poly (I:C) were able to induce 
significant cell proliferation in stimulated spleen cells (p 
< 0.05), sTLA + Poly (I:C) formulation had a tendency to 
reinforce this response (Fig. 5E).
These dataset highly indicated a Th1 bias cellular re-
sponse induced by the sTLA + Poly (I:C) immunisation.
sTLA formulated with Poly (I:C) provides partial 
protection against L. amazonensis infection - To deter-
mine the effectiveness of the immune response gener-
ated by a first-generation vaccine formulated with sTLA 
and Poly (I:C), different protection parameters were 
analysed: footpad swelling, splenic index and parasite 
burden (Fig. 6). Mice immunised with sTLA + Poly (I:C) 
showed a significant reduction in the size of their foot-
pad lesion as compared to the control mice (p < 0.001 
since nine weeks after challenge) or the group receiving 
sTLA in the absence of adjuvant (p < 0.01 since eight 
weeks after infection).
Furthermore, sTLA alone showed a significant in-
crease in their footpad swelling compared with con-
trol group (p < 0.01 since nine weeks after infection). 
The differences in the size of footpad lesion could be 
Fig. 4: humoral immune response in mice immunised with sonicated total Leishmania amazonensis antigens (sTLA) + Poly (I:C). Anti-
Leishmania IgG antibodies (A) using serum samples dilution (1:500) obtained two weeks after each immunisation. Anti-Leishmania IgG1 (B) 
and IgG2a (C) antibodies using serum samples dilution (1:500) obtained two weeks after boost. IgG2a/IgG1 ratio (C). Results are represented 
as mean ± standard error of mean (SEM) of optical density (OD) values obtained from six mice per groups. Asterisks indicate significant 
differences in comparison to the control group: ***p ˂ 0.001. & indicates statistically significant differences compared with the sTLA group: 
&&p < 0.01; &&&p < 0.001.
Fig. 5: cellular immune response generated in mice immunised with sonicated total Leishmania amazonensis antigens (sTLA) + Poly (I:C). 
Cytokines levels of IFN-γ (A), IL-4 (B), IL-10 (C) and IFN-γ / IL-10 ratio (D) were measured by enzyme-linked immunosorbent assay (ELISA) 
using supernatant of splenocytes stimulated with sTLA two weeks after the last boost; results are represented as mean ± standard error of 
mean (SEM) of cytokine concentration (pg) from six animals per group. Cell proliferation assay (E) was determined by MTT on stimulated 
splenocytes two weeks after the last boost; results are represented as mean ± SEM of proliferation index (ratio of unstimulated control) from six 
animals per group. Asterisks indicate significant differences in comparison to the control group: *p ˂ 0.05; **p ˂ 0.01; ***p ˂ 0.001. & indicates 
statistically significant differences compared with the sTLA group: &p < 0.05; &&&p < 0.001.
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noted macroscopically in the week nine after infec-
tion (Fig. 6A1, A2, A3).
Parasite burden and splenic index were determined 
11 weeks after infection. Mice immunised with sTLA 
+ Poly (I:C) showed a significant reduction of parasite 
burden in comparison to the group receiving sTLA alone 
(p < 0.05) but showed no difference in comparison to 
the control group (Fig. 6B). The splenic index of mice 
vaccinated with sTLA + Poly (I:C) was similar to non-
infected mice, exhibiting a more significant reduction 
than the control group (p < 0.05), which had an intense 
splenomegaly (Fig. 6C).
DISCUSSION
The research and development of vaccines against 
leishmaniasis began in the 20th century with first-gen-
eration vaccines comprising total Leishmania antigens. 
In the new world, Mayrink and Convit were the pioneers 
in the development of these prophylactic strategies, who 
produced total Leishmania antigens by ultrasound and 
pasteurisation to be combined with different adjuvant. 
These formulations showed to be immunogenic, safe 
and effective against cutaneous and/or mucocutaneous 
leishmaniasis.(13,24) In the 21st century, third generation 
vaccines were developed and evaluated, on the basis of 
recombinant proteins or DNA vectors.(25) Two veterinary 
vaccines against leishmaniasis based on recombinant 
antigens are already licensed.(26) Although many vaccine 
antigens have been identified in attempts to develop a 
Leishmania vaccine, only first-generation vaccines suc-
ceeded to reach phase III clinical trials.(15)
Even though different methodologies are used to 
obtain total Leishmania antigens for the development 
of first generation vaccines, no many studies have been 
conducted to compare the protein profile and immune 
response produced by these Leishmania antigens.(16)
Our study shows that the protein pattern of aTLA 
had a great loss of integrity and it was similar to that 
observed in other studies.(13) In concordance, the hu-
moral and cellular immune response induced by aTLA 
was very low. Otherwise, fTLA presented a conserved 
protein profile with a Th1:Th2:Tr1 mixed immune re-
sponse; this was also observed in our previous reports.(6) 
The comparison between protein integrity of pTLA and 
aTLA was similar to the one observed by Convit et al.(13) 
Finally, the integrity of proteins in ultrasound and fresh 
extracts had a notable similarity: protein profiles were 
essentially unaltered. In concordance, sTLA produced a 
strong humoral immune response.
Although splenocytes proliferation measurement in 
response to antigenic stimulation is not a direct corre-
lation of a specific effector function of T lymphocytes, 
it is reliable and widely used to assess the overall im-
munogenic features of antigenic proteins.(27) Our re-
sults demonstrate that only stimulated splenocytes from 
mice injected with sTLA had a statistically significant 
increase of cell proliferation. Thus, the increase in the 
cell proliferation index and the type of produced cyto-
kines indicate that sTLA activates a cellular immune re-
sponse characterised by higher levels of IFN-γ and cel-
lular proliferation than control (Fig. 3). However, it was 
not enough to protect against L. amazonensis infection, 
due to those immunised with sTLA developed a high in-
crease of footpad swelling and parasite load respect to 
control group (Fig. 6).
We previously demonstrated that subcutaneous vac-
cination with fTLA without an adjuvant increases the 
susceptibility of BALB/c mice to cutaneous leishmani-
asis.(6,19) Therefore, TLA induce an exacerbation of the 
infection independently of the methodology employed to 
obtain them. These results were in accordance to other 
authors, who demonstrated that whole-killed promasti-
gotes of L. amazonensis administrated to Rhesus mon-
keys via a subcutaneous route also showed an increase 
in experimental infections with follow up challenges 
with L. amazonensis.(28) This increased susceptibility to 
cutaneous leishmaniasis could be due to the presence 
of serine proteases in whole-killed promastigotes of L. 
amazonensis, which promote an enhanced production of 
IL-10 and activate a Th2-type immune response.(29)
In spite of the strong immune response induced by 
sTLA, it must be reinforced towards a better Th1-like 
immune response by an appropriated adjuvant. Our re-
sults disclose that Poly (I:C) improved the humoral im-
mune response of sTLA due to the adjuvant increased 
IgG2a levels and IgG2a/IgG1 ratio with respect to sTLA 
alone (Fig. 4).
Fig. 6: protection assay on immunised mice immunised with sonicated total Leishmania amazonensis antigens (sTLA) + Poly (I:C). Footpad 
swelling caused by challenge with infective promastigotes of L. amazonensis (A), and photograph of right footpad (RFP) taken nine weeks after 
infection from control (A1), sTLA (A2) and sTLA + Poly (I:C) (A3) groups. Parasite burden in infected footpads, the numbers of viable parasites 
were determined after 11 weeks of infection by a limit dilution assay (B). Splenic index was evaluated 11 weeks after infection (C). Values in the 
graphics represent the means ± standard error of mean (SEM) of footpad swelling (mm), parasite burden (-Log n° of parasites) or splenic index 
from 6 animals per group. The asterisks indicate statistically significant differences compared with the control group: *p < 0.05; **p < 0.01; 
***p < 0.001. & indicates statistically significant differences compared with the sTLA group: &p < 0.05; &&p < 0.01; &&&p < 0.001.
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Cytokine production and cell proliferation are differ-
ent methodologies to evaluate the cellular immune re-
sponse mediated by T-lymphocytes.(30) Our results dem-
onstrate that sTLA + Poly (I:C) enhanced this response, 
increasing IFN-γ production and cell proliferation. Even 
though this formulation also increased IL-4 production, 
it was lower than IFN-γ and it was accompanied by basal 
levels of IL-10; and it correlated with an increase of ratio 
IFN-γ/IL-10. It has been demonstrated that IL-10 has a 
significant role in infection progression,(31) so maintain-
ing low levels of IL-10 implies an improvement in the 
protective immune response.
Our previous results showed that Poly (I:C) formulat-
ed with TLA, obtained by cycles of freezing and thaw-
ing, was able to protect BALB/c mice against L. amazo-
nensis infection.(6) The present study confirms that Poly 
(I:C) combined with another TLA, obtained by ultra-
sound, also provides partial protection against cutane-
ous leishmaniasis. Protective response was reflected in 
a lower footpad lesion, splenic index and parasite load; 
however, it must be improved. The reduction in splenic 
index could be indirectly related to a decrease in parasite 
visceralisation,(32) an inflammatory responses and to a 
lower susceptibility to infection.(33) Despite of the most 
conserved protein profile of sTLA, our previous studies 
with fTLA demonstrated an apparent higher protection, 
with lower footpad swelling. However, a comparative 
experiment should be conducted.
In conclusion, the antigens obtained by ultrasound 
have a more conserved protein profile and induce an in-
tense immune response in immunised animals. These 
antigens formulated with a synthetic double-stranded 
RNA as adjuvant lead to an increase of IgG2a and IFN-γ, 
accompanied by basal levels of IL-10. These datasets 
highly suggest that sTLA + Poly (I:C) is an eligible formu-
lation to generate a balanced Th1/Th2 humoral and Th1 
cellular immune response that allows a partial protection 
against cutaneous leishmaniasis by L. amazonensis.
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